Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
Elisabeth H Thijssen,I. Verberk,9 Authors,C. Teunissen
2022 · DOI: 10.1002/dad2.12285
Alzheimer's & Dementia · 74 Citations
TLDR
This work explored what combination of blood‐based biomarkers differentiates Alzheimer's disease (AD) dementia, frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB).
Abstract
We explored what combination of blood‐based biomarkers (amyloid beta [Aβ]1‐42/1‐40, phosphorylated tau [p‐tau]181, neurofilament light [NfL], glial fibrillary acidic protein [GFAP]) differentiates Alzheimer's disease (AD) dementia, frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB).